Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Juan José Davidovich, general manager of the Italian ophthalmology leader Sifi, speaks about the importance of Mexico as a base to enter Latin America and sets the goal of prospering…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. The general manager for Mexico discusses the competitive advantages Mexico offered to start operations in Latin…
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
Since he took office in December 2012, President Enrique Peña Nieto has achieved much in terms of the number of major reforms passed in Mexico. Besides the most expected change…
During 2013 Mundipharma entered Brazil, Mexico and Colombia to consolidate its presence in the Latin American region. The general director for Mexico discusses the company’s plans to become leader in…
UCB has transformed into a specialty care pharma which focuses on bringing solutions to patients suffering from severe chronic diseases. The vice president and region head for Americas discusses how…
Mexico is one of GSK’s growth engines in Latin America. The VP and general manager for Mexico discusses how the country is increasingly playing a strategic role for the company…
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Indian companies are increasingly interested in tapping into the alluring Mexican and Latin American pharmaceutical markets. The general manager of the API and drug producer discusses the vision behind the…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Recognized by the University of Pennsylvania as one of the top 30 think tanks in the world for health policy, FUNSALUD is committed to propose solutions to Mexico’s most important…
See our Cookie Privacy Policy Here